Atrial fibrillation and bisphosphonate therapy

doi:10.1359/jbmr.091201

Perspective

You have free access to this content

Atrial fibrillation and bisphosphonate therapy

Michael Pazianas^1,*,
Juliet Compston²,
Christopher L-H Huang³

Article first published online: 20 JAN 2010

DOI: 10.1359/jbmr.091201

Issue

Journal of Bone and Mineral Research

Volume 25, Issue 1, pages 2–10, January 2010

Additional Information

How to Cite

Pazianas, M., Compston, J. and Huang, C. L.-H. (2010), Atrial fibrillation and bisphosphonate therapy. Journal of Bone and Mineral Research, 25: 2–10. doi: 10.1359/jbmr.091201

Author Information

¹
Institute of Musculoskeletal Sciences, University of Oxford, Headington, Oxford OX3 7LD, United Kingdom
²
Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, United Kingdom
³
Physiological Laboratory, University of Cambridge, Downing Street, Cambridge CB2 3EG, United Kingdom

Email: Michael Pazianas (Michael.Pazianas@ndorms.ox.ac.uk)

^*Institute of Musculoskeletal Sciences, University of Oxford, Headington, Oxford OX3 7LD, United Kingdom.

Publication History

Issue published online: 20 JAN 2010
Article first published online: 20 JAN 2010
Manuscript Accepted: 1 DEC 2010
Manuscript Revised: 20 NOV 2009
Manuscript Received: 19 JUL 2009

ARTICLE TOOLS

View Full Article (HTML) Get PDF (218K)

References

1
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285: 2370–2375.
2
Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008; 5: 30–41.
3
Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006; 27: 949–953.
4
Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008; 92: 17–40.
5
Drug Topics. Top 200 brand-name drugs by units in 2006. Available at: www.drugtopics.com/drugtopics/Pharmacy+Facts+And+Figures/Top-200-brand-name-drugs-by-units-in-2006/ArticleStandard/Article/detail/407649?contextCategoryId=7604. Accessed December 9, 2008.
6
Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809–1822.
7
PhVWP assessment report on bisphosphonates and atrial fibrillation. September 2008. Available at: http://docs.google.com/gview?a=v&attid=0.1&thid=1208109362726c8b&mt=application%2Fpdf&pli=1.
8
Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007; 356: 1895–1896.
9
Lyles KW, Colón-Emeric CS, Magaziner JS, et al. for the HORIZON Recurrent Fracture Trial. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007; 357: 1799–1809.
10
Karam R, Camm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med. 2007; 357: 712–713.
11
Sørensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008; 336: 813–816.
12
Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. 2009; 265: 581–592.
Direct Link:
13
Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008; 168: 826–831.
14
Food and Drug Administration (FDA). The FDA safety information and adverse event reporting program. Available at: www.fda.gov/medwatch/safety/2008/safety08.htm#bisphosphonates2. Accessed November 15, 2008.
15
Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS ONE. 2009; 4: e4720.
16
Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer. 2003; 98: 1735–1744.
Direct Link:
17
Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf. 2009; 32: 219–228.
18
Mak A, Cheung MW, Ho RC, Cheak AA, Lau CS. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized, controlled trials and observational studies. BMC Musculoskel Disord. 2009; 10: 113.
19
Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005; 20: 1912–1920.
Direct Link:
20
Corradi D, Callegari S, Maestri R, Benussi S, Alfieri O. Structural remodeling in atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008; 5: 782–796.
21
Beharier O, Etzion Y, Katz A, et al. Crosstalk between L-type calcium channels and ZnT-1, a new player in rate-dependent cardiac electrical remodeling. Cell Calcium. 2008; 42: 71–82.
22
Hirose M, Laurita KR. Calcium-mediated triggered activity is an underlying cellular mechanism of ectopy originating from the pulmonary vein in dogs. Am J Physiol Heart Circ Physiol. 2007; 292: H1861–1867.
23
Zhang Y, Schwiening C, Killeen MJ, et al. Pharmacological alterations of cellular Ca²⁺ homeostasis parallel initiation of atrial arrhythmogenesis in Langendorff perfused murine hearts. Clin Exp Pharmacol Physiol. 2009; 36: 969–980.
Direct Link:
24
Hove-Madsen L, Llach A, Bayes-Genis A, et al. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation. 2004; 110: 1358–1363.
25
Dobrev D, Nattel S. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J Cardiovasc Pharmacol. 2008; 52: 293–299.
26
Van Wagoner DR, Nerbonne JM. Molecular basis of electrical remodeling in atrial fibrillation. J Mol Cell Cardiol. 2000; 32: 1101–1117.
27
Rude RK. Magnesium depletion and hypermagnesemia. In: FavusMJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6th ed. Chap. 40 ASBMR Washington, DC: ASBMR; 2006: 230–233.
28
Miller S, Crystal E, Garfinkle M, Lau C, Lashevsky I, Connolly SJ. Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis. Heart. 2005; 91: 618–623.
29
Ho KM, Sheridan DJ, Paterson T. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis. Heart. 2007; 93: 1433–1440.
30
Severs NJ, Coppen SR, Dupont E, Yeh HI, Ko YS, Matsushita T. Gap junction alterations in human cardiac disease. Cardiovasc Res. 2004; 62: 368–377.
31
Gollob MH. Cardiac connexins as candidate genes for idiopathic atrial fibrillation. Curr Opin Cardiol. 2006; 21: 155–158.
32
Dupont E, Ko Y, Rothery S, et al. The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation. 2001; 103: 842–849.
33
Polontchouk L, Haefliger JA, Ebelt B, et al. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol. 2001; 38: 883–891.
34
Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res. 2002; 54: 361–379.
35
Dhein S, Duerrschmidt N, Scholl A, et al. A new role for extracellular Ca2+ in gap-junction remodeling: studies in humans and rats. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377: 125–138.
36
Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19: 733–759.
37
Colucci S, Minielli V, Zambonin G, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int. 1998; 63: 230–235.
38
Paspaliaris V, Leaver DD. Clodronate inhibits contraction and prevents the action of L-type calcium channel antagonists in vascular smooth muscle. J Bone Miner Res. 1991; 6: 835–841.
Direct Link:
39
Mönkkönen J, van Rooijen N, Ylitalo P. Effects of clodronate and pamidronate on splenic and hepatic phagocytic cells of mice. Pharmacol Toxicol. 1991; 68: 284–286.
Direct Link:
40
Kemeny-Suss N, Kasneci A, Rivas D, et al. Alendronate affects calcium dynamics in cardiomyocytes in vitro. Vascular Pharmacol. 2009; 51: 350–358.
41
Chen CL, Huang SK, Lin JL, et al. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J Mol Cell Cardiol. 2008; 45: 742–753.
42
Nakano Y, Niida S, Dote K, et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol. 2004; 43: 818–825.
43
Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S. Atrial ischemia promotes atrial fibrillation in dogs. Circulation. 2003; 107: 1930–1936.
44
Skalidis EI, Hamilos MI, Karalis IK, Chlouverakis G, Kochiadakis GE, Vardas PE. Isolated atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation. J Am Coll Cardiol. 2008; 51: 2053–2057.
45
Corradi D, Callegari S, Benussi S, et al. Myocyte changes and their left atrial distribution in patients with chronic atrial fibrillation related to mitral valve disease. Hum Pathol. 2005; 36: 1080–1089.
46
Corradi D, Callegari S, Benussi S, et al. Regional left atrial interstitial remodeling in patients with chronic atrial fibrillation undergoing mitral-valve surgery. Virchows Arch. 2004; 445: 498–505.
47
Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302: 1055–1061.
48
Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002; 62: 6538–6544.
49
Hamma-Kourbali Y, Di Benedetto M, Ledoux D, et al. A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Commun. 2003; 310: 816–823.
50
Sebbah-Louriki M, Colombo BM, el Manouni D, et al. A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects. Anticancer Res. 2002; 22: 3925–3931.
51
Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997; 57: 3890–3894.
52
Teronen O, Heikkilä P, Konttinen YT, et al. MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci. 1998; 878: 453–465.
Direct Link:
53
Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004; 114: 623–633.
54
Abdelhadi RH, Gurm HS, Van Wagoner DR, Chung MK. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am J Cardiol. 2004; 93: 1176–1178.
55
Mathew JP, Fontes ML, Tudor IC, et al. Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004; 291: 1720–1729.
56
Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997; 96: 1180–1184.
57
Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003; 108: 3006–3010.
58
Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006; 27: 136–149.
59
Boos CJ, Lip GY. Inflammation and atrial fibrillation: cause or effect? Heart. 2008; 94: 133–134.
60
Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005; 139: 101–111.
Direct Link:
61
Zandbergen HR, Sharma UC, Gupta S, et al. Macrophage depletion in hypertensive rats accelerates development of cardiomyopathy. J Cardiovasc Pharmacol Ther. 2009; 14: 68–75.
62
Goldstein RN, Ryu K, Khrestian C, van Wagoner DR, Waldo AL. Prednisone prevents inducible atrial flutter in the canine sterile pericarditis model. J Cardiovasc Electrophysiol. 2008; 19: 74–81.
- PubMed,
- Web of Science® Times Cited: 10
63
Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res. 2006; 69: 865–875.
64
Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J. 2004; 25: 1100–1107.
65
Yared JP, Bakri MH, Erzurum SC, et al. Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial. J Cardiothorac Vasc Anesth. 2007; 21: 68–75.
66
Halonen J, Halonen P, Järvinen O, et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA. 2007; 297: 1562–1567.
67
Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sørensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med. 2009; 169: 1677–1683.
68
Alberts AW, Chen J, Kuron G, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA. 1980; 77: 3957–3961.
69
Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998; 13: 581–589.
Direct Link:
70
Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA. 1999; 96: 133–138.
71
Rogers MJ. Statins: lower lipids and better bones? Nat Med. 2000; 6: 21–23.
72
Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res. 2004; 62: 105–111.
73
Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation. 2004; 110: 2313–2319.
74
Ashikaga H, Marine JE. Prevention of atrial fibrillation: another good reason to recommend statins to women? Heart. 2009; 95: 693–694.
75
Marín F, Pascual DA, Roldán V, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol. 2006; 97: 55–60.
76
Lertsburapa K, White CM, Kluger J, Faheem O, Hammond J, Coleman CI. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2008; 135: 405–411.
77
Pellegrini C, Vittinghoff E, Lin F, Hulley S, Marcus G. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: The HERS Trial. Heart. 2009; 95: 704–708.
78
Virani SS, Nambi V, Razavi M, et al. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J. 2008; 155: 541–546.

View Full Article (HTML) Get PDF (218K)

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Atrial fibrillation and bisphosphonate therapy

Journal of Bone and Mineral Research

How to Cite

Author Information

Publication History

ARTICLE TOOLS

References

More content like this

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Atrial fibrillation and bisphosphonate therapy

Journal of Bone and Mineral Research

How to Cite

Author Information

Publication History

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

References

More content like this